ERBB2 and cancer: Chemotherapy-induced cardiotoxicity (CIC) is an increasingly recognized complication in cancer survivors, particularly with anthracyclines, human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and immune checkpoint inhibitors.